참고문헌
- Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009;20:146-159.
- Center for Cancer Control and Information Services, National Cancer Center. Vital statistics [Internet]. Tokyo (JP): National Cancer Center, c2010 [cited 2013 Apr 18]. Available from: http://ganjoho.jp/professional/statistics/ statistics.html.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166
- Jung KW, Park S, Won YJ, et al. Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat 2012;44:25-31. https://doi.org/10.4143/crt.2012.44.1.25
- Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806-813. https://doi.org/10.1016/S0168-8278(02)00297-0
- Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415-423. https://doi.org/10.1634/theoncologist.2007-0252
- Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment:5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009;16:1-7. https://doi.org/10.1007/s00534-008-0015-0
- Sasaki T, Isayama H, Nakai Y, et al. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013;19:72-77. https://doi.org/10.3748/wjg.v19.i1.72
- Tada M, Nakai Y, Sasaki T, et al. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011;2:158-163. https://doi.org/10.5306/wjco.v2.i3.158
- Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600. https://doi.org/10.1093/oxfordjournals.annonc.a010676
- Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-f luorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998;45:2020-2026.
- Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581-4586. https://doi.org/10.1200/JCO.2010.29.3605
- Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. https://doi.org/10.1038/sj.bjc.6603648
- Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843-851. https://doi.org/10.1093/jjco/hym116
- Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapynaive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-1520. https://doi.org/10.1038/sj.bjc.6601736
- Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279-281. https://doi.org/10.1093/annonc/mdi046
- Kim ST, Park JO, Lee J, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006;106:1339-1346. https://doi.org/10.1002/cncr.21741
- Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study: The UK ABC-01 Study. Br J Cancer 2009;101:621- 627. https://doi.org/10.1038/sj.bjc.6605211
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281. https://doi.org/10.1056/NEJMoa0908721
- Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469-474. https://doi.org/10.1038/sj.bjc.6605779
- Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343. https://doi.org/10.1093/annonc/mdh351
- Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-852. https://doi.org/10.1038/sj.bjc.6603334
- Andre T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867. https://doi.org/10.1038/sj.bjc.6604628
- Kim HJ, Lee NS, Lee SC, et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371-377. https://doi.org/10.1007/s00280-008-0883-7
- Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010;65:641-647. https://doi.org/10.1007/s00280-009-1069-7
- Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005;104:2753-2758. https://doi.org/10.1002/cncr.21591
- Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338. https://doi.org/10.1200/JCO.2005.51.008
- Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307-1312. https://doi.org/10.1002/cncr.22902
- Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008;26:3702-3708. https://doi.org/10.1200/JCO.2008.16.5704
- Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004;91:1769-1774. https://doi.org/10.1038/sj.bjc.6602208
- Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008;62:849-855. https://doi.org/10.1007/s00280-007-0673-7
- Sasaki T, Isayama H, Yashima Y, et al. S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 2009;77:71-74. https://doi.org/10.1159/000226214
- Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010;65:1101-1107. https://doi.org/10.1007/s00280-009-1115-5
- Kanai M, Yoshimura K, Tsumura T, et al. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011;67:1429-1434. https://doi.org/10.1007/s00280-010-1443-5
- Sasaki T, Isayama H, Nakai Y, et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013;71:973-979. https://doi.org/10.1007/s00280-013-2090-4
- Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805) [abstract]. J Clin Oncol 2012;30(4 Suppl):abstr 255.
- Kim YJ, Im SA, Kim HG, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 2008;19:99-103. https://doi.org/10.1093/annonc/mdn320
- Kang MJ, Lee JL, Kim TW, et al. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol 2012;51:860-866. https://doi.org/10.3109/0284186X.2012.682628
- Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-1120. https://doi.org/10.1093/annonc/mdg281
- Hong YS, Lee J, Lee SC, et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007;60:321-328. https://doi.org/10.1007/s00280-006-0380-9
- Sanz-Altamira PM, O'Reilly E, Stuart KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001;12:501-504. https://doi.org/10.1023/A:1011135014895
- Alberts SR, Fishkin PA, Burgart LJ, et al. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 2002;32:107-114. https://doi.org/10.1385/IJGC:32:2-3:107
- Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-2310. https://doi.org/10.1200/JCO.1996.14.8.2306
- Papakostas P, Kouroussis C, Androulakis N, et al. Firstline chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract: a multicentre phase II study. Eur J Cancer 2001;37:1833-1838. https://doi.org/10.1016/S0959-8049(01)00214-3
- Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-3074. https://doi.org/10.1200/JCO.2005.05.3579
- Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777-783. https://doi.org/10.1007/s00280-009-0927-7
- Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010;102:68-72. https://doi.org/10.1038/sj.bjc.6605458
- El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2012;30:1646-1651. https://doi.org/10.1007/s10637-011-9719-0
- Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011;29:2357-2363. https://doi.org/10.1200/JCO.2010.33.9473
- Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010;28:3491-3497. https://doi.org/10.1200/JCO.2010.28.4075
- El-Khoueiry AB, Rankin C, Iqbal S, et al. SWOG 0941: a phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma [abstract]. J Clin Oncol 2012;30(15 Suppl):abstr 4113.
- Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010;11:1142-1148. https://doi.org/10.1016/S1470-2045(10)70247-3
- Malka D, Fartoux L, Rousseau V, et al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: final analysis of a randomized phase II trial (BINGO) [abstract]. J Clin Oncol 2012;30(15 Suppl):abstr 4032.
- Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-188. https://doi.org/10.1016/S1470-2045(11)70301-1
- Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11:48-54. https://doi.org/10.1016/S1470-2045(09)70333-X
- Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013;49:329-335. https://doi.org/10.1016/j.ejca.2012.08.003
- Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 2004;34:547-550.
- Sasaki T, Isayama H, Nakai Y, et al. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011;29:1488-1493. https://doi.org/10.1007/s10637-010-9485-4
- Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007;72:105-110. https://doi.org/10.1159/000111117
- Oh SY, Jeong CY, Hong SC, et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011;29:1066-1072. https://doi.org/10.1007/s10637-010-9417-3
- Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer [abstract]. J Clin Oncol 2010;28(15 Suppl):abstr 4145.
- Sasaki T, Isayama H, Nakai Y, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012;30:708-713. https://doi.org/10.1007/s10637-010-9553-9
- Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012;83:57-66. https://doi.org/10.1159/000338795
- Roth A, Schleyer E, Schoppmeyer K, et al. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie 2011;34:469-470. https://doi.org/10.1159/000331065
- Yi JH, Thongprasert S, Lee J, et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012;48:196-201. https://doi.org/10.1016/j.ejca.2011.11.017
- Katayose Y, Ohtsuka H, Kitamura Y, et al. An analysis of a second-line S-1 monotherapy for gemcitabinerefractory biliary tract cancer. Hepatogastroenterology 2012;59:691-695.
- Kobayashi S, Ueno M, Ohkawa S, et al. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 2012;42:800-806. https://doi.org/10.1093/jjco/hys102
- Sasaki T, Isayama H, Nakai Y, et al. A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer [abstract]. J Clin Oncol 2013;31(4 Suppl):abstr 258.
- Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:703-713. https://doi.org/10.6004/jnccn.2012.0073
- Sasaki T, Isayama H, Ito Y, et al. Comparing the treatment outcomes between unresectable and recurrent cases receiving gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer: pooled analysis of two prospective studies [abstract]. J Clin Oncol 2012;30(4 Suppl):abstr 331.
- Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531-3540. https://doi.org/10.1200/JCO.2009.27.4787
- Sasaki T, Isayama H, Nakai Y, et al. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 2011;67:847-853. https://doi.org/10.1007/s00280-010-1360-7
피인용 문헌
- Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis vol.74, pp.6, 2013, https://doi.org/10.1007/s00280-014-2608-4
- Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case vol.12, pp.None, 2013, https://doi.org/10.1186/1477-7819-12-326
- Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer vol.20, pp.48, 2013, https://doi.org/10.3748/wjg.v20.i48.18452
- Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens vol.9, pp.None, 2013, https://doi.org/10.2147/dddt.s86750
- Clinical outcomes of secondary gastroduodenal self‐expandable metallic stent placement by stent‐in‐stent technique for malignant gastric outlet obstruction vol.27, pp.1, 2013, https://doi.org/10.1111/den.12321
- Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades vol.2, pp.1, 2013, https://doi.org/10.2217/hep.14.36
- Surgery for Recurrent Biliary Tract Cancer: A Single-center Experience With 74 Consecutive Resections vol.262, pp.1, 2013, https://doi.org/10.1097/sla.0000000000000827
- Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review vol.47, pp.3, 2015, https://doi.org/10.4143/crt.2014.308
- Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis vol.9, pp.None, 2016, https://doi.org/10.2147/ott.s110926
- Metastasectomy for Recurrent or Metastatic Biliary Tract Cancers: A Single Center Experience vol.22, pp.1, 2013, https://doi.org/10.15746/sms.16.001
- Locally Advanced Gallbladder Cancer Treated with Chemotherapy and Subsequent Curative Resection vol.49, pp.12, 2016, https://doi.org/10.5833/jjgs.2016.0031
- CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy vol.49, pp.3, 2017, https://doi.org/10.4143/crt.2016.326
- Metastasectomy for recurrent or metastatic biliary tract cancers: A single center experience vol.54, pp.1, 2017, https://doi.org/10.4103/0019-509x.219581
- Metastatic Gallbladder Cancer Treated with Curative Surgery after Cyclic Chemotherapy and Biliary Drainage vol.23, pp.1, 2013, https://doi.org/10.15279/kpba.2018.23.1.41
- The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer : A STROBE-compliant retrospective cohort study vol.97, pp.50, 2018, https://doi.org/10.1097/md.0000000000013570
- Clinical outcomes after multiple self-expandable metallic stent placement using stent-in-stent technique for malignant gastric outlet obstruction vol.99, pp.21, 2013, https://doi.org/10.1097/md.0000000000019432
- Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era vol.25, pp.5, 2013, https://doi.org/10.1634/theoncologist.2019-0306
- Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer vol.14, pp.None, 2013, https://doi.org/10.2147/ijgm.s297371